What ChondroFiller actually does inside a damaged hip joint

If you have been told you have cartilage damage in your hip, you may be wondering whether an injection can actually do anything structural — or whether it simply masks pain for a few weeks the way a steroid might. ChondroFiller® liquid works through a fundamentally different principle.

It is an injectable collagen scaffold: a purified Type I collagen solution that, once placed inside the joint under ultrasound guidance, polymerises at body temperature to form a temporary three-dimensional matrix directly over the defect site. Crucially, it contains no donor cells. The scaffold is acellular — what it does is create the right physical and biochemical environment to recruit the patient's own progenitor cells from the surrounding synovium and subchondral bone. This process is known as acellular matrix-induced chondrogenesis: in plain terms, the injected structure acts as both a physical support and a chemical signal, drawing in the body's own mesenchymal and chondral cells and encouraging them to migrate into the matrix and begin repair work.

Over the following three to six months, those recruited cells progressively remodel the collagen scaffold into fibrocartilage-like repair tissue. As this happens, the original collagen matrix gradually resorbs, leaving behind tissue generated by the patient's own biology.

This distinguishes ChondroFiller clearly from viscosupplementation (hyaluronic acid injections), which lubricates the joint but does not provide a structural matrix for cell recruitment, and from hydrogel-based products whose role is mechanical cushioning rather than promoting endogenous repair. ChondroFiller is not a painkiller and does not deliver an immediate analgesic effect — its benefits develop as the repair tissue matures.

Which patients are most likely to benefit

Not every patient with hip pain is a candidate, and being clear about that upfront matters more than keeping the door open for everyone.

ChondroFiller is best suited to patients with a focal cartilage defect or early-to-moderate hip cartilage wear where imaging confirms genuine structural damage. The practical upper limit for a single defect is 6 cm² — beyond that area, the scaffold cannot provide adequate coverage. Multiple smaller defects may still fall within scope, depending on the overall picture.

MRI assessment is a prerequisite, not an optional step. At MSK Doctors the imaging review is built into the pathway: damage is mapped and suitability confirmed before any injection is considered. This protects patients from undergoing a procedure unsuited to their joint, and it ensures the treating consultant knows precisely where to place the scaffold.

Three absolute contraindications rule the treatment out entirely:

• Active joint infection — introducing any material into an infected joint is unsafe
• End-stage osteoarthritis with complete cartilage loss — there is no remaining tissue bed for the scaffold to work with
• Expectation of rapid, steroid-style pain relief — ChondroFiller works progressively over months; it is not an analgesic

For patients with more diffuse Kellgren-Lawrence Grade III or IV disease, the treatment goal shifts: rather than focal restoration, the aim becomes high cell retention and viscoelastic cushioning across a broader worn surface. Outcomes in that group differ from focal-defect use and should be discussed individually at consultation.

The four-stage ultrasound-guided hip injection pathway

The treatment unfolds across four distinct stages, each with a clear clinical purpose and a defined timeframe — so patients know exactly what to expect and when.

Stage 1 — MRI assessment and candidacy confirmation. Before any injection is considered, the treating consultant reviews cross-sectional imaging to map the cartilage defect precisely: its location, area, and depth. This step, already described as a prerequisite in the selection process, determines where the scaffold must be placed and confirms the defect falls within the treatable range.

Stage 2 — Ultrasound-guided injection. The injection itself takes place as an outpatient appointment, under local anaesthetic only. Real-time ultrasound guidance allows the consultant to direct the collagen scaffold to the exact defect site. No general anaesthetic, no operating theatre, and no overnight stay are required. (Arthroscopic delivery, by contrast, demands a dry joint bed and full surgical conditions — the injectable form of ChondroFiller is designed from the outset to work within a fluid joint environment, making outpatient image-guided placement mechanistically viable.) Intravenous antibiotic cover is included at this stage as a precautionary measure.

Stage 3 — Protected loading, weeks 1–6. Once the scaffold has been placed, a period of modified weight-bearing allows it to integrate with the surrounding tissue without being mechanically disrupted. This phase typically lasts four to six weeks and involves activity modification rather than strict immobilisation.

Stage 4 — Progressive remodelling, from three months onward. As the body's own cells colonise and remodel the matrix — a process described in detail in the first section — fibrocartilage-like repair tissue forms progressively. Meaningful structural change is typically evident from three to six months. Patients should understand this is not a rapid-relief treatment; the benefit builds as repair tissue matures.

What the clinical evidence shows — and where the gaps are

The strongest single dataset to date is the Jerosch et al. post-market clinical follow-up (PMCF) study, which recorded a mean IKDC improvement of 32.4 points — a gain that was not only sustained at three-year follow-up but marginally increased, with patients reaching a mean functional score of 80. That result sits well above the established Minimal Clinically Important Difference (MCID) of 16.7 points, the threshold at which patients themselves register a meaningful change in function. Across four prospective knee investigations, every study cleared that threshold, with average IKDC gains of approximately 30 points at 12 months.

Structural repair — not just reported function — is captured by MOCART MRI scoring. MOCART assesses defect filling, border integration, and tissue signal at the repair site; scores in European cohorts ranged from 81.6 to 84.3, indicating greater than 80% defect filling and good integration with surrounding native cartilage. The maturation pattern is informative in its own right: mean scores progressed from 65.3 at four weeks to 81.6 at 12 months, confirming that repair tissue continues to develop well after the injection itself.

All of this data comes from knee cohorts. These findings apply to the hip on mechanistic grounds — the collagen scaffold recruits host cells by the same biological process regardless of joint — but this remains an extrapolation rather than a direct demonstration. For the hip, functional outcomes are measured using the Harris Hip Score alongside MOCART MRI; dedicated prospective hip cohort data has not yet been published. That is an active area of ongoing research, and it does not diminish the mechanistic foundation or the structural evidence the knee studies have established.

Safety profile and how ChondroFiller compares with alternatives

Published safety data for ChondroFiller is reassuring. In reported cohorts, the complication rate is approximately 0% and the reoperation rate falls between 3% and 8% — meaning the large majority of patients who receive the injection do not require any further procedure on that joint.

For context, the two surgical alternatives most commonly discussed alongside ChondroFiller tell a different story. Microfracture — a widely used arthroscopic technique — carries a reoperation rate of up to 41% in published literature. ACI and MACI (autologous chondrocyte implantation and its matrix-assisted variant) achieve comparable functional improvements of around 30–35 IKDC points, but with complication rates reported up to 17% and reoperation rates up to 37%. ACI and MACI also typically involve two surgical stages: an initial arthroscopic biopsy to harvest chondrocytes, a laboratory cultivation period, and then a second operative procedure to implant the cultured cells — each stage carrying its own anaesthetic exposure and recovery burden. ChondroFiller's single-stage, ultrasound-guided outpatient pathway avoids that compounded procedural risk, which is a practical consideration for patients who are medically cautious about general anaesthesia or who cannot afford extended time away from work.

Other injection options — corticosteroid and hyaluronic acid — serve a different clinical role: symptom management rather than structural repair. Neither promotes endogenous cartilage regeneration, and neither addresses the underlying defect. They remain legitimate short-term tools in appropriate circumstances, but they are palliative in intent and should not be conflated with a scaffold-based regenerative pathway.

The right option for any individual depends on the defect size, joint condition, activity goals, and overall health — factors that only a full consultant assessment can weigh properly.

Getting assessed at MSK Doctors — no referral needed

MSK Doctors is a CQC-registered, consultant-led group — rated 'Good' across all five key inspection domains — and patients can book directly without a GP referral or NHS waiting list.

The ChondroFiller hip pathway is available at two sites in the East Midlands: the Sleaford clinic (NG34), which houses an Open MRI scanner and the group's Regeneration Hub, and the Grantham centre (NG31), which offers consultations and diagnostic assessment. Patients do not need to arrive with imaging already arranged — MRI assessment is the clinical starting point and is coordinated as part of the pathway.

ChondroFiller treatment is self-funded private care and is not currently available on the NHS or routinely reimbursed by private medical insurers. Guide cost is in the region of £2,995–£3,000, though patients should confirm current pricing at the point of booking, as this is subject to change. London-based readers can access the same treatment through the London Cartilage Clinic.

To book an assessment or find out whether you are a suitable candidate, visit mskdoctors.com — no referral required.